Page 86 - HIV/AIDS Guidelines

74. MooreR,KerulyJ,GallantJ.Tenofovirandrenaldysfunctioninclinicalpractice.Paperpresentedat:14thConference
onRetrovirusandOpportunisticInfections(CROI);Feb.25-28,2007;LosAngeles,CA.Abstract832.
75. KearneyBP,MathiasA,MittanA,SayreJ,EbrahimiR,ChengAK.Pharmacokineticsandsafetyoftenofovirdisoproxil
fumarateoncoadministrationwithlopinavir/ritonavir.J Acquir Immune Defic Syndr.Nov12006;43(3):278-283.
76. KiserJJ,CartenML,AquilanteCL,etal.Theeffectoflopinavir/ritonavirontherenalclearanceoftenofovirinHIV-
infectedpatients.Clin Pharmacol Ther.Feb2008;83(2):265-272.
77. GallantJE,MooreRD.Renalfunctionwithuseofatenofovir-containinginitialantiretroviralregimen.AIDS.Sep24
2009;23(15):1971-1975.
78. GoicoecheaM,LiuS,BestB,etal.Greatertenofovir-associatedrenalfunctiondeclinewithproteaseinhibitor-based
versusnonnucleosidereverse-transcriptaseinhibitor-basedtherapy.J Infect Dis.Jan12008;197(1):102-108.
79. McComseyGA,KitchD,DaarES,etal.Bonemineraldensityandfracturesinantiretroviral-naivepersonsrandomized
toreceiveabacavir-lamivudineortenofovirdisoproxilfumarate-emtricitabinealongwithefavirenzoratazanavir-
ritonavir:AidsClinicalTrialsGroupA5224s,asubstudyofACTGA5202.J Infect Dis.Jun2011;203(12):1791-1801.
80. StellbrinkHJ,OrkinC,ArribasJR,etal.Comparisonofchangesinbonedensityandturnoverwithabacavir-lamivudine
versustenofovir-emtricitabineinHIV-infectedadults:48-weekresultsfromtheASSERTstudy.Clin Infect Dis.Oct15
2010;51(8):963-972.
81. DeJesusE,HerreraG,TeofiloE,etal.Abacavirversuszidovudinecombinedwithlamivudineandefavirenz,forthe
treatmentofantiretroviral-naiveHIV-infectedadults.Clin Infect Dis.Oct12004;39(7):1038-1046.

82. SaxPE,TierneyC,CollierAC,etal.Abacavir/LamivudineVersusTenofovirDF/EmtricitabineasPartofCombination
RegimensforInitialTreatmentofHIV:FinalResults. J Infect Dis.Oct2011;204(8):1191-1201.

83. PostFA,MoyleGJ,StellbrinkHJ,etal.Randomizedcomparisonofrenaleffects,efficacy,andsafetywithonce-daily
abacavir/lamivudineversustenofovir/emtricitabine,administeredwithefavirenz,inantiretroviral-naive,HIV-1-infected
adults:48-weekresultsfromtheASSERTstudy.J Acquir Immune Defic Syndr.Sep12010;55(1):49-57.
84. MallalS,PhillipsE,CarosiG,etal.HLA-B*5701screeningforhypersensitivitytoabacavir.N Engl J Med.Feb7
2008;358(6):568-579.
85. SaagM,BaluR,PhillipsE,etal.Highsensitivityofhumanleukocyteantigen-b*5701asamarkerforimmunologically
confirmedabacavirhypersensitivityinwhiteandblackpatients.Clin Infect Dis.Apr12008;46(7):1111-1118.
86. SabinCA,WormSW,WeberR,etal.Useofnucleosidereversetranscriptaseinhibitorsandriskofmyocardialinfarctionin
HIV-infectedpatientsenrolledintheD:A:Dstudy:amulti-cohortcollaboration.Lancet.Apr262008;371(9622):1417-1426.
87. ChoiAI,VittinghoffE,DeeksSG,WeekleyCC,LiY,ShlipakMG.Cardiovascularrisksassociatedwithabacavirand
tenofovirexposureinHIV-infectedpersons.AIDS.Jun192011;25(10):1289-1298.
88. DurandM,SheehyO,BarilJG,LelorierJ,TremblayCL.AssociationbetweenHIVinfection,antiretroviraltherapy,and
riskofacutemyocardialinfarction:acohortandnestedcase-controlstudyusingQuebec'spublichealthinsurance
database.J Acquir Immune Defic Syndr.Jul12011;57(3):245-253.

89. ObelN,FarkasDK,KronborgG,etal.AbacavirandriskofmyocardialinfarctioninHIV-infectedpatientsonhighly
activeantiretroviraltherapy:apopulation-basednationwidecohortstudy.HIV Med.Feb2010;11(2):130-136.

90. TheSMART/INSIGHTandtheD:A:DStudyGroupsTSIatDADSG.Useofnucleosidereversetranscriptaseinhibitors
andriskofmyocardialinfarctioninHIV-infectedpatients.AIDS.Sep122008;22(14):F17-24.

91. RibaudoHJ,BensonCA,ZhengY,etal.Noriskofmyocardialinfarctionassociatedwithinitialantiretroviraltreatment
containingabacavir:shortandlong-termresultsfromACTGA5001/ALLRT.Clin Infect Dis.Apr12011;52(7):929-940.

92. DingX,Andraca-CarreraE,CooperC,etal.NoassociationofmyocardialinfarctionwithABCuse:AnFDAmeta-
analysis.Paperpresentedat:18thConferenceonRetrovirusesandOpportunisticInfections(CROI);Feb.27-Mar.2.2011;
Boston,MA.Abstract808.
93. BedimoRJ,WestfallAO,DrechslerH,VidiellaG,TebasP.Abacaviruseandriskofacutemyocardialinfarctionand

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents F-25

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.